Thinly traded nano cap Tiziana Life Sciences (NASDAQ:TLSA) is the latest coronavirus play. Shares are up on average volume in reaction to its announcement that candidate TZLS-501 may be a potential treatment for COVID-19 patients at risk of respiratory failure.
The company says it plans to administer TZLS-501,
an interleukin 6 (IL-6)-inhibiting monoclonal antibody, using a
proprietary formulation technology, adding that excess production of
IL-6 is a key driver of chronic inflammation and is believed to play a
key role in severe lung damage seen with COVID-19 infection and acute
respiratory illness.
https://seekingalpha.com/news/3550476-tiziana-life-sciences-up-306-premarket-on-potential-coronavirus-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.